Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
about
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinomaChromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasFluorescence In situ Hybridization: Cell-Based Genetic Diagnostic and Research ApplicationsMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerConvergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatmentMolecular biomarker analyses using circulating tumor cellsDevelopment of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridQuantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaImmunohistochemistry as an important tool in biomarkers detection and clinical practice.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsHistoFlex--a microfluidic device providing uniform flow conditions enabling highly sensitive, reproducible and quantitative in situ hybridizations.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaConcomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationOptical fiber-based in vivo quantification of growth factor receptors.Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisQuantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissuesEvaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoIncreased expression of Gp96 by HBx-induced NF-κB activation feedback enhances hepatitis B virus productionAssociation between HSP90 and Her2 in gastric and gastroesophageal carcinomas.Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.Systems approaches to molecular cancer diagnostics.A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisAnalysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.The new cytogenetics: blurring the boundaries with molecular biology.Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samplesPalindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumorsNF-kappa B-mediated adaptive resistance to ionizing radiation.The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.Development of a single-cell array for large-scale DNA fluorescence in situ hybridization.HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Benefits, issues, and recommendations for personalized medicine in oncology in CanadaShould adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.State-of-the-art FISHing: automated analysis of cytogenetic aberrations in interphase nuclei.The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma.Evaluation of HER2 in breast cancer: reality and expectations.
P2860
Q24536023-8812EE76-DAB5-48B8-93CC-5E973D2351B5Q26865068-5C1E0D39-4FD2-45C0-965A-8971FA56FC84Q28069679-0314F716-4D94-4D47-B8B1-D40723B11BC9Q28072513-C0597F91-13E5-4AAD-AC62-087816514A9FQ28243455-BB50F586-6521-4550-8937-AFD1717135A6Q28749394-F8B81516-3894-43D6-9DD0-25471DDB2DADQ33378811-4949BE5B-F418-46E2-81C7-C58A71E531BDQ33421127-325F3E7B-C521-4920-919D-7BD15E85A04FQ33704442-A8E8677F-E69E-4D0C-A1DA-0F680F7AB5DFQ33812042-91902CFA-4C8F-4BDE-8963-6AD74312DE51Q34037296-5F56C797-36F9-4974-9AE0-7B9B74329716Q34064466-697F8588-E66F-43B9-B6C3-BCC10DA2DA62Q34084063-3AA73851-C5EA-4BEB-BFC1-F4CC1C4FC097Q34226408-61CF68FB-7698-4971-B6E6-7307385B039CQ34359802-D5A81924-DD40-45A9-B1CC-D5F80C6FC7DEQ34493341-F4BC4DFF-66BF-4D65-BEC3-02AC52B2E987Q34501712-0040B5BC-782E-4926-9BFA-58C7E137D16AQ34640536-75A65417-8519-4DAB-BC4E-2B8A518DFBE0Q34775798-6C4EE7E2-FA8F-4705-BD5A-03B42E824A94Q34852929-0B3F1CA9-CB0E-4600-8326-E60A762A836CQ35078787-E301C040-0FC2-4C6B-8EB6-8AE43804587AQ35162461-5AEF895F-169E-498F-A466-6E767F2650BEQ35186717-A2838943-67A2-4B4E-A4D9-744006A1DCD8Q35744973-91D3DC69-6EBE-46BF-986B-C5A8B019E090Q35778406-1323D6A9-47AD-4748-8CB8-A5A95B3D7C5CQ35789621-0D221743-390D-4892-9287-0F960797A2E4Q35810073-2859324F-C0C1-4A06-B0FD-1C8B1E2973E2Q36250557-664C2A97-ACF7-43F7-B049-A1843A8814D9Q36261449-50317EAE-A2D2-4A5D-BA60-3CDD5EEC2B38Q36283885-5D75865D-7121-4F52-9A36-8065CAA858ADQ36493029-7508C1BA-68C3-4457-8161-B013EA407F87Q36561648-AC3865DF-BCBE-451F-A7A5-DCB39B2F36CEQ36675265-FE232DFD-7E41-41C5-9E44-68F4345D8C5AQ36698389-98D3FB5A-C00D-4651-B322-EF321CC0138AQ37206247-3F56A69D-4C5F-4D52-ABD9-333FCBEB21DFQ37248023-C25D09AA-AFCD-4D76-8932-095C1EFD26A2Q37701327-ADE9DC59-6CC3-4306-AB2C-86D65F1E60F1Q38018578-5F5B992D-82D3-4756-9E5D-9EC596619B99Q38072066-86C29962-4D18-49BB-A0F6-08007C08B5A5Q38089837-6BB73546-3961-4ACB-B389-BD794A1E652B
P2860
Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Assessment of the HER2 status ...... with interpretive guidelines.
@ast
Assessment of the HER2 status ...... with interpretive guidelines.
@en
type
label
Assessment of the HER2 status ...... with interpretive guidelines.
@ast
Assessment of the HER2 status ...... with interpretive guidelines.
@en
prefLabel
Assessment of the HER2 status ...... with interpretive guidelines.
@ast
Assessment of the HER2 status ...... with interpretive guidelines.
@en
P1433
P1476
Assessment of the HER2 status ...... with interpretive guidelines.
@en
P2093
David G Hicks
Raymond R Tubbs
P304
P356
10.1016/J.HUMPATH.2004.11.010
P407
P577
2005-03-01T00:00:00Z